A humanized Type II anti-CD20 antibody comprising (a) a heavy chain variable region as depicted in SEQ ID NO:1 or as comprised in SEQ ID NO:5 (amino acid residues 1 to 119) and a light chain variable region as depicted in SEQ ID NO:2 or as comprised in SEQ ID NO:6 (amino acid residues 1 to 115); or (b) a heavy chain variable region that is encoded by a nucleic acid sequence which is at least 80% identical to SEQ ID NO:3 or SEQ ID NO:7 and a light chain variable region that is encoded by a nucleic acid sequence which is at least 80% identical to SEQ ID NO:4 or SEQ ID NO:8, wherein said antibody is capable of causing an increased antibody-dependent cellular cytotoxicity (ADCC) as compared to rituximab, is capable of causing an increased antibody-dependent cellular phagocytosis (ADCP) as compared to rituximab and/or has an increased affinity for FcγRIII receptors as compared to rituximab, for use in the treatment of diffuse large B-cell lymphoma (DLBCL) in a patient which responds to a treatment with obinutuzumab by reaching an improved clinical outcome as compared to a treatment with rituximab, wherein said patient is (i) a patient with one or more mutation(s) in one or more of the gene(s) selected from the group consisting of CREBBP, EP300, MEF2B, MYC, EZH2 and TNFRSF14; (ii) a patient with (a) genetic mutation(s) in CD58 and/or with a low expression of CD58 that corresponds to log2(normalized Reads Per Kilobase Million (nRPKM)) ≤ 5.2; (iii) a patient with a cell-of-origin subtype of DLBCL being germinal-center B-cell-like DLBCL as defined by a Linear Predictor Score <1141 (strong-GCB DLBCL); and/or (iv) a BCL2-translocated DLBCL patient and/or a DLBCL patient with high BCL2 expression wherein ≥50% of the tumor cells express BCL2. (a) a heavy chain variable region as depicted in SEQ ID NO:1 or as comprised in SEQ ID NO:5 (amino acid residues 1 to 119) and a light chain variable region as depicted in SEQ ID NO:2 or as comprised in SEQ ID NO:6 (amino acid residues 1 to 115); or (b) a heavy chain variable region that is encoded by a nucleic acid sequence which is at least 80% identical to SEQ ID NO:3 or SEQ ID NO:7 and a light chain variable region that is encoded by a nucleic acid sequence which is at least 80% identical to SEQ ID NO:4 or SEQ ID NO:8, wherein said antibody is capable of causing an increased antibody-dependent cellular cytotoxicity (ADCC) as compared to rituximab, is capable of causing an increased antibody-dependent cellular phagocytosis (ADCP) as compared to rituximab and/or has an increased affinity for FcγRIII receptors as compared to rituximab, for use in the treatment of diffuse large B-cell lymphoma (DLBCL) in a patient which responds to a treatment with obinutuzumab by reaching an improved clinical outcome as compared to a treatment with rituximab, wherein said patient is (i) a patient with one or more mutation(s) in one or more of the gene(s) selected from the group consisting of CREBBP, EP300, MEF2B, MYC, EZH2 and TNFRSF14; (ii) a patient with (a) genetic mutation(s) in CD58 and/or with a low expression of CD58 that corresponds to log2(normalized Reads Per Kilobase Million (nRPKM)) ≤ 5.2; (iii) a patient with a cell-of-origin subtype of DLBCL being germinal-center B-cell-like DLBCL as defined by a Linear Predictor Score <1141 (strong-GCB DLBCL); and/or (iv) a BCL2-translocated DLBCL patient and/or a DLBCL patient with high BCL2 expression wherein ≥50% of the tumor cells express BCL2. (i) a patient with one or more mutation(s) in one or more of the gene(s) selected from the group consisting of CREBBP, EP300, MEF2B, MYC, EZH2 and TNFRSF14; (ii) a patient with (a) genetic mutation(s) in CD58 and/or with a low expression of CD58 that corresponds to log2(normalized Reads Per Kilobase Million (nRPKM)) ≤ 5.2; (iii) a patient with a cell-of-origin subtype of DLBCL being germinal-center B-cell-like DLBCL as defined by a Linear Predictor Score <1141 (strong-GCB DLBCL); and/or (iv) a BCL2-translocated DLBCL patient and/or a DLBCL patient with high BCL2 expression wherein ≥50% of the tumor cells express BCL2.